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ATPaseHsp90 inhibitors are currently tested in clinical trials as anticancer agents. We investigated whether inhibitor
resistance may arise as a result of a point mutation in Hsp90. We used yeast cells that expressed human
Hsp90β to select inhibitor-resistant mutants from the randomly mutagenized library. Single amino acid
substitution, I123T, in a selected mutant was sufﬁcient to confer inhibitor resistance. Transfection of human
cells with the HSP90β I123T and the corresponding HSP90α I128T yielded cell lines resistant to inhibitors of
the Hsp90 ATPase. Unexpectedly, mutations did not result in diminished inhibitor binding in vitro. Similarly
resistant cells were obtained after transfection with previously described A116N and T31I mutants of HSP90β
that cause increase in ATPase activity in vitro. Inhibitor-resistant phenotypes of the I123T and A116N
mutants depended on their increased afﬁnity for Aha1, whereas T31I mutation did not result in increased
Aha1 binding. These results show possible scenario by which resistance may arise in patients treated with
Hsp90 inhibitors. Additionally, our results show that each isoform of Hsp90 can alone sustain cellular
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Heat shock protein 90 (Hsp90) is a highly conserved molecular
chaperone essential for the viability of eukaryotic cells (for review see
[1,2]). Hsp90 machinery is required for proper conformation,
activation and function of hundreds of client proteins involved in
virtually all cellular processes.
Human genome contains two genes that encode highly homolo-
gous cytoplasmic isoforms of Hsp90, α and β (hHsp90α, hHsp90β).
These isoforms exist in a cytoplasm as homodimers. To date, only few
examples of substrates speciﬁcally regulated by one of the Hsp90
isoforms exist in literature, such as hHsp90β-dependent regulation of
cell differentiation by c-IAP1 and progesterone receptor maturationby GCUNC-45 [3,4]. hHsp90α, but not hHsp90β, chaperones proteo-
lytic intermediates in the MHC Class I antigen processing pathway [5].
An enhanced interaction of the hHsp90α with various substrates
during heat shock was also reported [6]. Little is known about effects
of deletion or inactivation of one of the cytoplasmic hHsp90 isoforms.
Disruption of both alleles of HSP90β does not seem to be detrimental
for viability of chicken DT40 cells [7]. However, HSP90β knockout in
mice resulted in lethality in embryonic development indicating
necessity of this protein for the proper formation of placental
labyrinth [8]. There are no data on the effects of Hsp90α inactivation
other than results of short-term cultures made with isoform-speciﬁc
small interfering RNA (siRNA). In particular, mouse HSP90α knockout
was never reported, probably due to the fact that oocytes express
almost exclusively this isoform [9].
Hsp90 ATPase activity is essential for its chaperoning action
(reviewed in [1]). The most notable structural rearrangement in the
N-terminal domain that occurs upon ATP binding is movement and
remodeling of the structure known as the “lid” consisting of amino acids
94–125 in yeast yHsp90 (103–135 in hHsp90β) [10]. This change
leads to N-domains dimerization, structure compaction and ATPase
activation. These changes are believed to be directly responsible for the
576 A. Zurawska et al. / Biochimica et Biophysica Acta 1803 (2010) 575–583maintenance of competent state of substrates. Several cochaperones
were shown to interactwithHsp90dependingon its ATP-binding status
and modulate its ATPase activity. Sba1/p23 interacts with the ATP-
boundN-domain of Hsp90 and stabilizes compacted conformation, thus
inhibitingATPase activity [11,12]. In contrast to p23, Aha1 is the only co-
chaperone that upon binding to Hsp90 stimulates ATPase activity by
rearrangement of the active site [13–15].
Two natural compounds, radicicol and geldanamycin, and their
chemically modiﬁed analogues such as 17-(Allylamino)-17-
demethoxygeldanamycin (17-AAG) were identiﬁed as inhibitors of
theHsp90 that competewithATP for the binding site in theN-terminal
domain [16–19]. Hsp90 has become an attractive target for anticancer
therapy, due to its general function in maintaining various pathways
perturbed in cancer progression, such as growth signaling, apoptosis,
angiogenesis and metastasis (for review see [20]). ATP competing
inhibitors are currently tested in clinical trials [21].
Here we present novel hHsp90 mutants that render human and
yeast cells resistant to Hsp90 inhibitors. We show that the resistance
depends on the increased ATPase turnover due to enhanced
interaction with Aha1.
2. Materials and methods
2.1. Yeast strains
HSP82 and HSC82 genes were replaced with a G418 resistance
marker in the haploid strains SEY6210 and SEY6211 [22] as described
previously [23]. These strains were mated and the resulting diploid
was transformed with plasmid expressing hHSP90β and URA3 genes.
Transformants were subjected to sporulation and random spore
dissection [24]. The haploid strain BY516 that carried deletions of both
yeast HSP90 genes was selected based on its inability to lose plasmid
assayed by grow on 5-FOA containing media [24]. Deletions in this
strain were conﬁrmed by PCR with HSC82 and HSP82 speciﬁc primers.
Strain BY516 was used to construct strain BY517 by transformation
with plasmid pB549 (p423TDH3-hHSP90β) followed by selection for
HIS+ ura− phenotype. Yeast strains that expressed different alleles of
Caenorhabditis elegans or human Hsp90 as a sole source of this protein
were obtained by transformation of strain BY517 with plasmids
obtained by cloning different forms of Hsp90 into plasmid p416TDH3.
Transformants were selected for the histidine prototrophy and loss of
the HIS3 marker.
The library of the mutagenized hHSP90β alleles was used to
transform strain BY516. Transformants were selected on media
lacking histidine. Transformed colonies were collected in pools, each
containing about 1000 clones, ten pools in total. Pools were tested for
the radicicol resistance in liquid YPD medium supplemented with
5 µM radicicol. Only one pool grew up to saturation whereas growth
of the remaining nine pools was completely inhibited. Radicicol-
resistant clones were colony-puriﬁed and used to isolate plasmids
containing mutated alleles of hHSP90β. Growth of the yeast strains
carrying wild-type and mutant hHSP90 was monitored by the optical
density at 600 nm.
2.2. Plasmids
Yeast TDH3 promoter was ampliﬁed by PCR from the yeast
genomic DNA and used to replace GAL1 promoter in plasmids
p416GAL1 and p423GAL1 [25]. The resulting plasmids, p416TDH3
and p423TDH3, were used for expression of the human and C. elegans
HSP90 genes in yeasts. For expression in human cells, wild-type and
mutant alleles of hHSP90α and hHSP90β (I128T and I123T respec-
tively) with N-terminal FLAG and HA tags were cloned into the
pcDNA3.1(+) vector. Sequences of the PCR primers used to generate
inserts and detailed information on plasmids generated for this study
are provided in Supplementary Tables 1 and 2. Random mutationswere introduced into hHSP90β sequence during PCR ampliﬁcation
with Taq polymerase. To increase mutation rate, product of the ﬁrst
ampliﬁcation was used as a template in the next PCR reaction. Re-
ampliﬁcation was repeated four times. Product of the fourth round of
the ampliﬁcation was cloned in p423TDH3 vector, yielding a library of
about 10000 independent clones. Site-directed mutagenesis was
performed by PCR with mutagenic primers.
2.3. Cell line experiments
Plasmids carrying wild-type and various mutants of the hHSP90α
and hHSP90β were transfected into human cell lines using
Lipofectamine 2000 (Invitrogen) according to manufacturer's instruc-
tions. Transfectants were selected in the IMDM supplemented with
10% FCS and 1 mg/ml G418. This initial selection was followed by the
selectionwhereG418was replacedwith 1 µM17-AAG.Measurements
for the growth curves and IC50 of human cells were performed using
CellTiter-Glo reagent (Promega) according to the manufacturer's
protocol. For Aha1 knockdown cells were transfected with Silencer
Select siRNA (Applied Biosystems/Ambion, cat. no. s20802, s20903)
according to the manufacturer's instructions. Radicicol, 17-AAG and
17-DMAG were purchased from Sigma.
2.4. Protein expression and puriﬁcation for geldanamycin-binding and
ATPase assays
Humanwild-typeand I128Tmutant ofhHSP90α andC. elegansdaf-21
were cloned in vector pTYB4 (New England Biolabs). Expression of the
proteins was carried out in Escherichia coli BL21 strain. Proteins were
puriﬁed by an afﬁnity chromatography according to the New England
Biolabs recommendations, followed by the chromatography on heparin
and mono-Q sepharose. Human AHA1 was cloned in pET28 vector
(Novagen) to obtain C-terminal His-tagged fusion and was puriﬁed by
chromatography on Talon resin (Invitrogen).
2.5. In vitro assays
Geldanamycin immobilized on agarose beads was prepared
according to [26]. Geldanamycin-beads were incubated with puriﬁed
Hsp90 proteins in buffer containing 100 mMNaCl, 20 mM Tris pH 7.5,
1% BSA and 0.1% Triton X-100 and washed four times with the same
buffer. Bound proteins were eluted with SDS-loading buffer and
visualized by western blotting with an anti-Hsp90 antibody. ATPase
activity was measured by direct hydrolysis of the ATP γ-P33. Reaction
was performed in a buffer containing 25 mM Hepes–KOH pH 7.5,
25 mM KCl, 5 mM MgCl2, 1 mM ATP and 1 μM ATP γ-P33. Samples
containing Hsp90 protein at the 10 µM concentration and Aha1 (when
indicated) were incubated at 37° for 2 h. Produced radioactive
phosphate was separated from the substrate by the TLC chromatog-
raphy, radioactivity was assessed using Storm Phosphoimager
(Amersham Biosc.) and quantiﬁed with ImageQuant 5 software.
Activity of the non-speciﬁc ATPases contaminating Hsp90 prepara-
tions was measured under the same conditions with addition of the
200 µM radicicol. Obtained values as well as the value of non-speciﬁc
ATPases contamination of Aha1 preparation were used to correct
measured Hsp90 activities.
2.6. Western blot and co-immunoprecipitation
FLAG-speciﬁc antibody covalently linked to agarose beads (Sigma)
was used to precipitate FLAG-HA-tagged exogenous hHsp90 protein.
Western blot with anti-HA antibody was used to conﬁrm that equal
amounts of the precipitated hHsp90were loaded on the gel in each case.
Aha1 was detected using Aha1-speciﬁc ab56721 antibody (Abcam),
GAPDH with sc-32233 antibody (Santa Cruz). hHsp90 was detected
with SPA 846 antibody (Stressgen). To detect speciﬁc isoforms SPS 771
Fig. 1. Growth of yeast and human cells that express different mutants of hHsp90 on
media supplemented with Hsp90 inhibitors. (a) yeast strains that express indicated
forms of hHsp90 and C. elegans daf-21 as a sole source of this protein were grown on
YPD with different concentrations of radicicol for 4 days. Growth was measured on 96-
well plates as OD600. Plot presents representative results of one of the three
independent experiments. (b) Growth of HEK293 cells transfected with indicated
mutants of hHSP90 cultured on media with 1 μM 17-AAG was measured using
luciferase-based assay. Results were plotted in arbitrary luminometric units. (c) Growth
of HEK293 cells transfected with indicated mutants of hHSP90 in 17-AAGwasmeasured
as in (b). Results in (b) and (c) represent mean and SD values from three independent
experiments
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Bioreagents) were used.
2.7. Modeling
Computational studies were carried out on the structure of single
N-domain of the yHSP90 (Protein Data Bank code 1AM1, 2.0 Å
resolution) and on the structure containing all three domains (N, M
and C) of the yHSP90 (PDB code 2CG9, 3.1 Å resolution). In both
structures the loop containing V114 (residues 97–121) is clearly
visible and temperature factors for atoms in this loop are within range
15–50 for 1AM1 structure in within range 70–75 for 2CG9 structure.
YASARA software v. 9.1.25 (YASARA Biosciences) using Yamber3
forceﬁeld (modiﬁcation of Amber 99 forceﬁeld) was used for protein
visualization and modiﬁcation (mutation V114T). Subsequent opti-
mization was performed only for the part of protein structure
containing amino acids within 1.0 nm around modiﬁed residue.
2.8. Isothermal titration calorimetry
ITC experiments were carried out on VP-ITC isothermal titration
calorimeter (Microcal Inc., MA, USA) with the active cell volume of
1.4315 ml. The concentration of wild-type or mutant Hsp90α protein
in the cell was 6–10 μM, while the syringe contained 60–100 μM of
17-AAG, radicicol or Aha1. For the titrations of Hsp90with Aha1 in the
presence of 17-AAG, 20 μM of 17-AAG was added to both, the cell
and the syringe, to saturate the Hsp90 binding sites. Stock solutions of
17-AAG or radicicol were prepared in DMSO at 10–50 mM concen-
tration and stored at−20 °C. The ITC buffer contained 20 mM HEPES,
pH 7.5, 25 mMNaCl, and up to 1% DMSO. Titrationswere carried out at
25 °C, using 25 injections of 10 μl each, injected at 200 second
intervals. All experiments were repeated at least twice. Radicicol was
purchased from A. G. Scientiﬁc, Inc, 17-AAG and geldanamycin were
purchased from Sigma.
2.9. Protein preparation for ITC
Humanwild-type and I128Tmutant of hHSP90αwere inserted into
pET-15 vector (Novagen). Proteins with N-terminal His6-tag were
expressed in E. coli strain BL21 (DE3) and puriﬁed as previously
described [27]. Puriﬁed proteins were dialyzed against the storage
buffer: 20 mM Tris, pH 7.5, 50 mM Na2SΟ4 and 1 mΜ DΤΤ and stored
at −80 °C. Human AHA1 was cloned in pET-28 vector (Novagen) to
obtain the C-terminal His6-tag fusion. Protein was expressed in E. coli
strain BL21 (DE3) and puriﬁed using a Ni-IDA afﬁnity column
(Amersham Biosciences), followed by an anion exchange chromatog-
raphy on Q-sepharose (Amersham Biosciences). Protein was stored at
−80 °C in a buffer containing 20 mM HEPES, pH 7.5, 0.5 M NaCl and
0.5 mΜ DTT. For ITC experiments proteins were dialyzed against ITC
buffer and/or concentrated using Microcon ﬁlter devices (Milipore)
and resuspended in the ITC buffer.
3. Results
3.1. Selection of the radicicol-resistant Hsp90 mutants
We used an error-prone Taq polymerase to introduce random
mutations into hHSP90β coding sequence. Ampliﬁcation yielded a
population of hHSP90β alleles containing a single nucleotide substi-
tution every 50–60 bp. We created a library of these PCR products in a
yeast vector under the promoter of the glyceraldehyde-3-phosphate
dehydrogenase gene. To select for the radicicol-resistant mutants, we
transformed the library into a yeast strain which carried the deletion
of yHSC82 and yHSP82 genes and a plasmidwith hHSP90β gene. One of
these transformants was able to grow in liquid YPD medium in the
presence of 5 µM radicicol. Plasmid isolated from radicicol-resistantyeast carried hHSP90β gene that contained multiple single amino acid
substitutions (Suppl. Fig. 1). To ﬁnd the mutations responsible for the
radicicol-resistant phenotype, we introduced these mutations sepa-
rately in the human hHSP90β ORF cloned in a yeast expression vector.
Tests of the resulting plasmids demonstrated that substitution of the
single amino acid, I123T, is sufﬁcient to confer the radicicol-resistant
phenotype on yeast, whereas growth of the control strain transformed
with plasmid that carried wild-type hHSP90β was completely
inhibited, despite similar expression level of both proteins (Suppl.
Figure 2a). It was shown previously that yeast cells expressing daf-21,
the C. elegans homolog of Hsp90, were able to grow in the presence of
the Hsp90 inhibitors [28]. Yeast that expressed I123T mutant of
hHsp90β or hHSP90α I128T mutant that corresponds to I123T in
hHsp90β demonstrated equal or greater resistance to radicicol when
compared to daf-21 (Fig. 1a). Compared to wild-type hHsp90,
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fold respectively. The corresponding IC50 values were 0.5 µM for both
wild-type proteins, 6 µM for hHsp90β I123T and 10 µM for hHsp90α
I128T. Similar results were obtained for geldanamycin and 17-AAG,
however, due to the low sensitivity of yeast to these drugs the effect
was less pronounced (Suppl. Figure 3).3.2. Selection and growth of the inhibitor-resistant human cells
Transfection of the HEK293 cells with plasmids containing
hHSP90α I128T and hHSP90β I123T mutants, followed by selection
with 17-AAG allowed us to establish cell lines that were able to grow
continuously in media supplemented with 1 µM 17-AAG. Similarly
treated cells transfected with plasmids carrying wild-type hHSP90
genes or plasmid pcDNA3.1 did not acquire inhibitor resistance and
died after 8–10 days of culture (Fig. 1b and Suppl. Fig. 4a). This
transformation and selection process was repeated 9 times at
different occasions, always resulting in resistance after transformation
with mutants, whereas transformation with wild-type Hsp90's never
yielded 17-AAG resistant cells. Growth rate of the cells resistant to 17-
AAG cultured in a presence of this inhibitor and cells transfected with
control plasmid grown without inhibitor were nearly identical,
indicating that either isoform of hHsp90 is able to perform all
chaperone functions essential for growth of HEK293 cells (Suppl.
Fig. 4b). The IC50 of the hHSP90β I123T and hHSP90α I128T
transfectants was in 5 µM, compared to 0.5 µM for the cells
transfected with wild-type hHsp90 α and β (Fig. 1c). We observed
similar difference in resistance of the mutated and wild-type
transfectants to other inhibitors of Hsp90 — 17-DMAG and radicicol
(Suppl. Fig. 5). Expression of the exogenous wild-type and mutant
hHsp90 after transfection was similar (Suppl. Fig. 2b). We observed
moderate and sometimes dramatic increase in the expression of
exogenous Hsp90 after exposure to 17-AAG depending on the initial
transfection efﬁciency and whether transfectants were pre-selected
for the G418 resistance (Fig 2a, Suppl. Fig. 2b). This, together with
substantial cell death 3–8 days after beginning of selection, suggests
that during selection on 1 µM 17-AAG only cells with highest
expression of the mutated Hsp90 proteins survived. The exogenous
Hsp90 in cells after selection reached levels equal to or higher than
that of the endogenous protein (Fig. 2b, Suppl. Fig. 2b). Further
increase of the 17-AAG concentration did not result in additional
increase in the Hsp90 mutant production (Fig. 2b). This observation
shows that cells do not beneﬁt from increasing of the Hsp90 synthesis
beyond level sufﬁcient to acquire initial resistance to inhibitor.Fig. 2. Expression of the hHsp90α I128T and hHsp90β I123T mutants in HEK293 cells.
(a) Exogenous Flag-HA-tagged hHsp90 was detected with anti-HA antibody in protein
extracts from the cells before and after selection with 1 μM 17-AAG . (b) Cells
transfected with hHsp90β I123T and selected on 1 μM 17-AAG were grown on media
with increased concentrations of 1 μM 17-AAG. Anti-Hsp90 antibody (SPA 846) was
used to detect exogenous, tagged hHsp90β I123T (upper band) and endogenous
hHsp90β (lower band). Lane C represents transfected cells before 17-AAG selection.3.3. Inhibitor-resistant mutants bind 17-AAG and radicicol
We hypothesized that decreased afﬁnity for radicicol and
geldanamycin might be responsible for resistance to inhibition of
the Hsp90 mutants. Therefore we tested binding of the wild-type
hHsp90α and hHsp90α I128T to geldanamycin immobilized on
agarose beads. We compared these proteins with daf-21, C. elegans
homolog of Hsp90, that does not bind geldanamycin [29]. We did not
detect any daf-21 binding, whereas both hHSP90α proteins demon-
strated similar interaction with geldanamycin (Fig. 3).
We have used hHsp90alpha I128T, but not hHsp90beta I123T,
mutant in all in vitro experiments since the expression of the latter in
E. coli was very poor.
We also measured the binding of 17-AAG and radicicol to wild-
type and I128T mutant of hHsp90α by isothermal titration calorim-
etry (ITC). Titration curves are shown in Fig. 4 a–b and the values of
dissociation constant (Kd) are listed in Table 1. Wild-type protein
showed a slightly stronger binding of 17-AAG (Kd∼0.3 μM) compared
to I128T mutant (Kd∼1.0 μM). However, there was no detectable
difference in radicicol binding to wild-type and mutant protein
(Kd∼0.5 nm for both proteins). It is unlikely that small difference in
17-AAG binding between two proteins contributes substantially to
the inhibitor-resistant phenotype of the mutants.
3.4. 17-AAG resistant alleles of Hsp90 have increased afﬁnity for Aha1
A pull-down assay of the Hsp90 mutants with immobilized
geldanamycin and calorimetric measurements excluded decreased
inhibitor binding as a likely explanation of their resistance to
inhibition. In a search for an alternative explanation, we used co-
immunoprecipitation to compare binding of cochaperones to the
wild-type and mutated hHsp90. Results presented on Fig. 5a
demonstrate that hHsp90α I128T and hHsp90β I123T mutants bind
Aha1 proteinmuch stronger than wild-type hHsp90α or hHsp90β. This
suggests that stimulation of ATPase activity of the mutants by Aha1
binding most likely resulted in a decreased sensitivity to competitive
inhibitors of the Hsp90 ATPase such as radicicol and 17-AAG in vivo.
We noticed also that both wild-type and mutant hHsp90α had higher
afﬁnity for Aha1 than hHsp90β.
We also studied the interaction of Aha1 with the wild-type and
mutant form of hHsp90α by ITC in the absence or presence of 17-AAG.
The ITC curves showed a striking difference in Aha1 binding to the
wild-type hHsp90 (Fig. 4c) and I128T mutant (Fig. 4d). Wild-type
protein bound Aha1 with the Kd of ∼3 μM, while the Kd obtained for
mutant protein was ∼0.02 μM (Table 1), showing more than 100
times higher afﬁnity of Aha1 for Hsp90 mutant compared to wild-
type. The presence or absence of 17-AAG had essentially no effect on
Aha1 binding to hHsp90 proteins (Fig. 4c–d).
3.5. Stimulation of the ATPase activity results in the inhibitor resistance
of hHsp90
Two mutations that increased ATPase activity of the yHsp82, T22I
and A107N (T31I and A116N in the hHsp90β sequence, respectively),Fig. 3. Mutant and wild-type Hsp90 bind geldanamycin with similar afﬁnity.
Geldanamycin immobilized on agarose beads was used to pull-down puriﬁed wild-
type hHsp90α, hHsp90α I128T or C. elegans daf-21.
Fig. 4. Isothermal titration calorimetry of wild-type and I128T mutant of Hsp90α with 17-AAG, radicicol, and Aha1. All experiments were performed at 25 °C. Errors shown in the
table are standard deviations or uncertainties of the ﬁt of the data, whichever is greater. (a) ITC curve of 17-AAG (△) or radicicol (■) binding to wild-type Hsp90α. (b) ITC curve of
17-AAG (△) or radicicol (■) binding to mutant Hsp90α I128T. (c) ITC curves of Aha1 binding to wild-type Hsp90α in the absence (■) or presence (△) of 20 μM 17-AAG. (d) ITC
curves of Aha1 binding to I128T mutant in the absence (■) or presence (△) of 20 μM 17-AAG.
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carrying T31I or A116N mutants yielded cells that grew in a presence
of 1 µM 17-AAG with IC50 values similar or greater to IC50 for
hHsp90β I123T and hHsp90α I128T transfectants (Fig. 1c). Results of
the co-immunoprecipitation presented on Fig. 5b demonstrate that
A116N mutation caused the increased afﬁnity for Aha1. In contrast,Table 1
Dissociation constant of 17-AAG, radicicol and Aha1 binding to wild-type Hsp90α and
I128T mutant, obtained by isothermal titration calorimetry.
Protein
(in the cell)
Ligand/protein
(in the syringe)
Kd, μMa n, mol/
molb
ΔH, kcal/
molc
Hsp90α wt 17-AAG 0.3±0.06 1.03±0.01 −10.2±0.3
Hsp90α I128T 17-AAG 1.0±0.3 1.07±0.02 −15.2±0.4
Hsp90α wt Radicicol 0.0005±0.0002 0.99±0.03 −14.4±0.2
Hsp90α I128T Radicicol 0.0005±0.0002 0.98±0.02 −15.3±0.3
Hsp90α wt Aha1 3.0±1.5 0.40±0.15 −10±4
Hsp90α
wt+17-AAG
Aha1+17-AAG 3.0±1.5 0.55±0.12 −11±4
Hsp90α I128T Aha1 0.02±0.004 0.47±0.02 −17±1.6
Hsp90α I128T+
17-AAG
Aha1+17-AAG 0.015±0.005 0.43±0.01 −18±1.8
a Kd — dissociation constant.
b n — stoichiometry of binding.
c ΔH — enthalpy of binding.T31I mutation located on the opposite surface of the Hsp90 N-
terminal domain did not cause the increase in Aha1 binding. These
results point at the importance of the “lid” structure, containing
amino acids 116 and 123, for the interaction with Aha1. When we
transfected cells with anti-Aha1 siRNA, we observed marked decrease
in Aha1 expression up to 48 h after transfection. Decreased level ofFig. 5. Hsp90 mutants in the “lid” structure interact strongly with Aha1. (a–b) HEK293
cells transfected with Flag-HA-tagged mutant and wild-type forms of hHsp90 were
cultured for 24 h before immunoprecipitation with or without 1 µM 17-AAG. hHsp90.
Flag-HA-hHsp90 was precipitated using anti-FLAG antibodies immobilized on agarose
beads. Aha1 and hHsp90 eluted from beads were detected with anti-Aha1 and anti-HA
antibodies respectively.
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in slower growth that was not worsened further by the addition of
17-AAG (Fig. 6).We noticed similar effect of Aha1 silencing in the cells
transfected with the wild-type hHsp90β. However, cells carrying
mutation T31I were less sensitive to the decreased expression of
Aha1. These results underscore the differences between “Aha1-
dependent” A116N and I123T mutants and “Aha1-independent”
T31I mutant. The A116N mutation was previously predicted to
stabilize closed “lid” conformation by interaction of the aspartateFig. 6. Inhibitor resistance of I123T and A116Nmutants depends on Aha1. Cells that expresse
and non-speciﬁc siRNA (NS RNAi). (a) expression of Aha1 in cells transfected with contro
cultured with and without 1 µM 17-AAG. Growth curves were plotted in arbitrary lumino
experiments.with residues within the N-terminal domain [10]. We have used
molecular modeling to explain augmented Aha1 binding by I123T
mutant. Based on our model, we predicted that a closed conformation
of the I123T mutant (corresponding to V114T in yHsp82) is stabilized
by interaction of threonine114 with arginine 346 located in the
middle domain (R366 and R358 in hHsp90 α and β respectively). On
the other hand, such mutation destabilizes hydrophobic interactions
of V114 with the loop 22–26 in the open conformation of the lid
(Fig. 7a–b).d indicated mutants of Hsp90βwere transfected with Aha1-speciﬁc siRNA (Aha1 RNAi)
l and Aha1-speciﬁc siRNA 48 h after transfection. (b) growth curves of transfectants
metric units. Error bars represent standard deviation calculated from 3 independent
Fig. 7. Computational modeling of the V114T mutation in the yHsp82 structure. (a) in a model based on the complex of HSP90 N-domain with ADP loop containing V114T (residues
97–121 in green) is ordered (contains α-helix). (b) binding of ATP causes large movement of 97–121 loop (in green) and this loop stays disordered. The catalytic loop 377–381
(orange) protrudes to the space occupied previously by loop 97–121.
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stimulated by Aha1 in vitro
We measured ATPase activity of the puriﬁed wild-type and I128T
mutant of hHsp90α. Both proteins demonstrated similar ATPase
activity in the absence of Aha1 (Fig. 8). However, upon addition of
Aha1, the rate of ATP hydrolysis by the hHsp90α I128T increased at
lower Aha1 concentration. At equimolar concentration of Aha1
ATPase activity of hHsp90α I128T mutant was 3-fold higher
compared to wild-type hHsp90α.
4. Discussion
Yeast was previously used as a model system to assay properties of
different Hsp90 proteins [30,31]. We used this system to select for the
hHsp90 inhibitor-resistant mutants from a library of plasmids with
randomly mutagenized hHSP90β genes. We identiﬁed mutation I123T
that is sufﬁcient for the inhibitor resistance in yeasts. This mutation is
localized in a highly conserved region of the N-terminal domain,
known as the “lid” [10]. Mutants hHsp90α I128T and hHsp90β I123TFig. 8. Stimulation of the ATPase activity of hHsp90α and hHsp90α I128T with Aha1.
Constant amount of the puriﬁed hHsp90 was mixed with Aha1 at different molar ratios
and incubated for 30 min at 20 °C. After that time, the reaction was initiated by addition
of ATP-γ P33. Error bars represent standard deviation calculated from 3 independent
experiments.introduced into HEK293 human cells allowed us to select cell lines
that were 17-AAG resistant, whereas introduction of the wild-type
alleles into the cells, therefore increasing the wild-type protein level,
does not protect the HEK293 cells against the inhibitors. Our
experiments provide for the ﬁrst time evidence that point mutations
in Hsp90 may induce resistance to 17-AAG in human cells. Hsp90 is a
potential attractive target for an anti-cancer therapy and the ATPase
inhibitors attract a lot of attention [20,32,33]. Selection of the cells
that acquired resistance to inhibitors of oncogenic kinases is a well
known problem in therapy [34–36]. Our results indicate that similar
process may lead to mutational alterations of Hsp90 resulting in
acquired resistance to ATPase inhibitors. So far no mutations in genes
encoding Hsp90 in human cells were identiﬁed that would alter
Hsp90 activity. However, predicted wide use of Hsp90 inhibitors as
anti-cancer drugs may favor selection of such mutations. Such
scenario is further supported by our results indicating that inhibitor
tolerance could be in principle induced by whole class of mutations
increasing ATPase activity, irrespectively of the exact localization of
these mutations in HSP90 protein.
The increased expression of Hsp90 in cancer cells, sometime
correlated with decreased survival of the patients, was reported in
several studies [37–39]. This increased expression is most likely a
physiological adaptation that compensates an increased requirement
for the Hsp90 chaperoning activity in actively proliferating cells and
by itself does not give cells extra protection from Hsp90 inhibitors.
Our data that expression of transfected Hsp90 does not increase
resistance of the cells to inhibition supports this explanation.
Decreased expression or activity of NQO1 oxidoreductase was
reported previously as a mechanism of the acquired resistance for 17-
AAG and 17-DMAG [40]. The involvement of other oxidoreductases
was also postulated [41]. To exclude that inhibitor resistance of our
cells depends on the oxidoreductase activity we tested them for
resistance for radicicol. Unlike 17-AAG and 17-DMAG, toxicity of
radicicol does not depend on the reduction to hydroquinone.
Resistance of our cell lines to radicicol proved that this phenotype
was not NQO1 dependent. We observed inhibitor resistance only in
cultures transfected with mutated hHsp90s and never in cultures
transfected with the wild-type hHsp90s. Therefore we concluded that
these mutations are sufﬁcient to cause resistance and no mutations or
changes in expression of other genes are involved.
One naturally occurring geldanamycin-resistant Hsp90 homo-
logue, C. elegans daf-21, was previously described and it was shown
that this protein was unable to bind geldanamycin [29]. Amino acids
582 A. Zurawska et al. / Biochimica et Biophysica Acta 1803 (2010) 575–583changed in the inhibitor-resistant human Hsp90s are conserved in
daf-21, indicating that the mechanism of their resistance may not
involve decreased afﬁnity to geldanamycin. In pull-down in vitro
experiments I128T mutant and wild-type hHsp90α bound geldana-
mycin equally well. Moreover, ITC measurements of 17-AAG and
radicicol binding also did not show dramatic changes in the afﬁnity of
hHsp90α I128T for the inhibitor. Relatively small, 3-fold increase in Kd
of the I128Tmutantmay contribute to the resistance phenotype, but it
is unlikely to explain more than 10-fold increase in the resistance
observed in vivo.
Binding of Aha1 to both hHsp90β I123T and hHsp90α I128T was
dramatically increased. We found that hHsp90β A116N mutation,
previously reported to increase ATPase activity in vitro, also resulted
in an increased afﬁnity for Aha1 in vivo. Unambiguous results were
obtained from ITC assays, which showed that I128T mutation
increased the afﬁnity of hHsp90α for Aha1 over 100 times.
Results of the ATPase activity assays reﬂected increased Aha1
binding to hHsp90α I128T mutant compared to wild-type. Both
proteins hydrolyzed ATP at a similar rate when Aha1 was not present.
However, upon addition of Aha1 ATPase activity of the I128T mutant
increased at lower Aha1 concentrations and reached higher maximal
level. Our ﬁndings that a strong Aha1 binding by hHsp90 may protect
it from ATPase inhibitors complement earlier report that decreased
Aha1 expression causes hyper sensitivity to 17-AAG [42]. Our results
suggest that changes in Aha1 expression level may affect effectiveness
of the Hsp90 ATPase inhibitors in treatment of particular tumors.
Aha1 was reported as a cochaperone that binds to the middle
domain of Hsp90 and stimulates ATPase activity by moving arginine
380 (yHsp82) closer to the catalytic site [13,15]. However, afﬁnity of
Aha1 for the full-length Hsp90 is almost 6 times higher than for the
middle domain, suggesting that interaction involves also N-terminal
or C-terminal domain of Hsp90 [15]. Our results provide for the ﬁrst
time evidence that sequences located in the N-terminal part of
hHsp90β, in particular amino acids 116 and 123, are important for the
Aha1–Hsp90 interaction. These residues lie within the “lid” structure
(amino acids 108–139 in hHsp90α and 103–134 in hHsp90β), which
is predicted to undergo structural remodeling upon ATP binding and
hydrolysis [10]. According to our model T123 (T128) may stabilize
“lid” in a closed conformation by interaction with R358 (R366) in the
middle domain. This interaction may increase stability of the Hsp90–
Aha1 complex by promoting conformational change that naturally
occurs upon Aha1 binding. Isoleucine 123 is involved in Hsp90–p23
complex formation and mutation of this residue could affect function
of p23 [43]. However, we did not see obvious negative inﬂuence of the
I123T mutation on the growth of the cells that could be attributed to
the decreased p23–Hsp90 afﬁnity. Moreover, I123T mutation did not
affect p23 binding to Hsp90 in the co-immunoprecipitation experi-
ment (result not shown). Therefore we concluded that the effect of
I123T substitution is most likely restricted to Hsp90–Aha1 interaction.
To test whether an increased ATPase activity is sufﬁcient for the
inhibitor resistance we studied properties of two mutations that in
yHsp90 constitutively increased rate of ATP hydrolysis in vitro [10].
These mutants carried T22I and A107N substitutions. Transfections of
the human cells with corresponding hHsp90β mutants (T31I and
A116N) yielded cells that grew continuously on 17-AAG but only
A116N mutation increased Hsp90–Aha1 binding, whereas T31I
mutant demonstrated wild-type afﬁnity for Aha1. Similar 17-AAG
growth phenotypes of A116N and T31I mutants despite differences in
their ability to bind Aha1 support conclusion that high ATPase activity
and not co-chaperone binding is crucial for the inhibitor resistance.
These observations, together with results of the geldanamycin-
binding assay, strongly suggest that increased rate of ATP hydrolysis
is sufﬁcient for the cells to acquire resistance to the whole class of the
ATPase competitive inhibitors, even if afﬁnity of these inhibitors to
ATP-binding site is not diminished. Our results complement also
previous report that located in the lid segment yHsp90 T101Imutation, that causes severe decrease of the ATPase activity and
decreased expression of Aha1, results in the radicicol and geldana-
mycin sensitive phenotype [30,42].
It was shown before that the other Hsp90 co-chaperone, HOP/Sti1,
contributes to the inhibitor resistance in yeast [30] most likely due to
the decreased binding afﬁnity of inhibitor to Hsp90–Sti1 complex,
compared to Hsp90 alone [44]. Recently published results proved that
Sba1/p23 has also protective effect against inhibitors of Hsp90 [45].
Sba1 binds to the N-terminal domain of Hsp90 and decreases rate of
ATP hydrolysis, resulting in the stabilization of the ATP-bound form of
Hsp90 [12]. An interaction of Sba1 with Hsp90 also decreases Hsp90
afﬁnity for ATPase inhibitors [45]. Therefore, Aha1, Sti1 and Sba1
binding to Hsp90 can reverse effects of Hsp90 inhibitors, but the
mechanism of action of each co-chaperone is different.
In the cells transfected with hHsp90α I128T or hHsp90β I123T
only these proteins remain active when activity of the endogenous
Hsp90α and β is blocked by 17-AAG present in the medium. In all
respects, most of the Hsp90 chaperoning activity in these cells is
provided by sole isoform of Hsp90. Therefore, our results proved that
neither hHsp90 isoform is essential for the viability of HEK293 cells,
even in cultures lasting for several weeks.
A radicicol-resistant mutant of the S. cerevisiae Hsp90, designed
basing on the structural information on Hsp90 from the radicicol-
resistant yeast H. fuscoatra was recently reported [46]. This work
demonstrated that replacing amino acids crucial for radicicol binding
results in resistance to this inhibitor but not to geldanamycin. In
contrast, we demonstrated thatmutations of amino acids not involved
directly in binding of ATP or inhibitor may confer resistance to two
different types of inhibitors: radicicol and 17-AAG.
In conclusion, we demonstrated for the ﬁrst time that various
single amino acid substitutions can result in Hsp90 resistance to
known inhibitors. Resistance for inhibitors does not correlate with
decreased binding afﬁnity for inhibitor of the mutated Hsp90. We
provided genetic and biochemical evidence that the “lid” region
located in N-terminal domain of Hsp90 is crucial for interaction with
Aha1 in addition to the described Aha1 binding site in the middle
domain of Hsp90. Our results suggest also that the expression level of
Aha1 in a cancer cells may be a valuable prediction factor for the
efﬁciency of the Hsp90 inhibitors in therapy.
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